SAN ANTONIO (July 2, 2015) — More than 220,000 men in the United States will be diagnosed with prostate cancer this year; more than 27,000 will die from it. It’s the most common cancer to strike men, but new treatments are available for even advanced prostate cancers.
Two leading oncologists from the Cancer Therapy & Research Center at the UT Health Science Center San Antonio will speak on these innovations and take questions from the audience in a free public presentation on Thursday, July 9, at the CTRC.
“Emerging evidence from our work and that of others is that for high-risk prostate cancers, combinations of treatments are much more effective in helping control cancers,” said CTRC Director Ian M. Thompson Jr., M.D., “We’re proud to have helped develop and lead these studies, and it’s our goal to share this information with the community so that people can educate themselves on the options.”
Dr. Thompson will be joined by Devalingam Mahalingam, M.D., Ph.D., an oncologist at the CTRC and associate professor in the School of Medicine at the UT Health Science Center, who will talk about advances in immunotherapy and hormone therapy.
“The treatment standard for patients with castration-resistant prostate cancer is changing,” Dr. Mahalingam said. “Apart from chemotherapy, now we have a variety of novel hormonal therapies, immunotherapy and radioisotopes that gives patients more options in fighting their cancer with fewer side effects.”
The presentation will be Thursday, July 9, from 5:30 to 7 p.m. at the CTRC, 4th Floor Grossman Building, 7979 Wurzbach Road, San Antonio. For more information call (210) 450-1152.
The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit www.ctrc.net.